Utah Medical Products, Inc. Reports Corrected Results of Tender Offer
SALT LAKE CITY, UT / ACCESS Newswire / October 29, 2026 / On September 24, Utah Medical Products, Inc. (Nasdaq:UTMD) offered to purchase up to 650,000 shares of its common stock at $75.00 per share. The issuer Tender Offer expired Tuesday October 27.
In short, 327,740 shares were purchased for $24,580,500. Remaining UTMD shares outstanding at this date are 2,849,041 including 1,775 employee option shares exercised in October.
In addition, $107,720 administration fees will be paid to the depositary and information agent, and $6,732 in filing fees to the SEC. The effective cost of the tender offer was 75.35/ share. Another 1% excise tax will be levied by the federal government on share repurchases.
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website atwww.utahmed.com.
Contact:
Brian Koopman
(801) 566-1200
SOURCE: Utah Medical Products, Inc.
View the original press release on ACCESS Newswire
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
This Once-Hot AI Stock Now Looks Deeply Undervalued
What 7 Key Market Indicators Are Telling Investors Right Now
Don’t Overlook the Income Side of Fixed Income
United States